108656-64-0

Basic information

• Product Name: 5-(2-BROMO-PHENYL)-[1,3,4]THIADIAZOL-2-YLAMINE
• Synonyms: 5-(2-BROMOPHENYL)-1,3,4-THIADIAZOL-2-AMINE;5-(2-BROMO-PHENYL)-[1,3,4]THIADIAZOL-2-YLAMINE
• CAS NO: 108656-64-0
• Molecular Formula: C₈H₆BrN₃S
• Molecular Weight: 256.12
• Mol File: 108656-64-0.mol
• Article Data: 13

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-(2-BROMO-PHENYL)-[1,3,4]THIADIAZOL-2-YLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(2-BROMO-PHENYL)-[1,3,4]THIADIAZOL-2-YLAMINE(108656-64-0)
• EPA Substance Registry System: 5-(2-BROMO-PHENYL)-[1,3,4]THIADIAZOL-2-YLAMINE(108656-64-0)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• Hazardous Substances Data: 108656-64-0(Hazardous Substances Data)

Usage

General Description

5-(2-Bromo-phenyl)-[1,3,4]thiadiazol-2-ylamine, also known as BPTA, is a chemical compound that belongs to the class of thiadiazole derivatives. It is a potential drug candidate with various biological activities, including anti-cancer and anti-inflammatory properties. BPTA has been studied for its potential as an anti-cancer agent, showing promising results in inhibiting the growth of cancer cells. It has also been investigated for its anti-inflammatory properties, demonstrating potential as a treatment for inflammatory diseases. BPTA is a valuable chemical compound with potential applications in pharmaceutical and biomedical research.

Upstream product

• 333-20-0 potassium thioacyanate 
• 158918-49-1 N’-(2-bromobenzylidene)-4-methylbenzenesulfonohydrazide 
• 7420-34-0 2-(2-bromobenzylidene)hydrazinocarbothioamide 
• 6630-33-7 ortho-bromobenzaldehyde 
• 79-19-6 thiosemicarbazide 
• 88-65-3 2-bromobenzoic-acid 
• 7420-34-0 (E)-2-bromobenzaldehyde thiosemicarbazone 

Downstream Products

• 259794-76-8 [5-(2-Bromo-phenyl)-[1,3,4]thiadiazol-2-yl]-[1-phenyl-meth-(E)-ylidene]-amine 
• 1634721-11-1 N-(5-(2-bromophenyl)-1,3,4-thiadiazole-2-yl)-2-(3-oxo-1,2-benzothiazol-2(3H)-yl)acetamide 
• 1248828-39-8 2-[{5-(2-bromophenyl)-[1,3,4]-thiadiazol-2-yl}imino]-5-(3,4-dimethoxybenzylidene)-1,3-thiazolidin-4-one 
• 1248828-29-6 5-benzylidene-2-[{5-(2-bromophenyl)-[1,3,4]-thiadiazol-2-yl}imino]-1,3-thiazolidin-4-one 
• 1248828-22-9 2-[{5-(2-bromophenyl)-[1,3,4]-thiadiazol-2-yl}imino]-1,3-thiazolidin-4-one 
• 1248828-17-2 2-chloro-N-[5-(2-bromophenyl)-[1,3,4]-thiadiazol-2-yl]-acetamide 

Relevant articles and documents

N-(5-phenyl-1, 3, 4-thiadiazole-2-yl) benzamide compound

The invention belongs to the technical field of medicines, relates to a compound with antitumor activity and a specific chemical structure, and in particular relates to an N-((6, 7-dimethoxyquinoline-4-yl) oxy) methyl)-N-(5-phenyl-1, 3, 4-thiadiazole-2-yl) benzamide compound and a preparation method and an application thereof. The structural general formula of the compound is shown in the specification, wherein an R group is mono-substituted or double-substituted phenyl, fluorophenyl, chlorphenyl, bromophenyl, benzyl, benzyloxy, benzene nitro or trifluoromethyl substituted at 2-position, 3-position or 4-position. Pharmacological studies show that the compound provided by the invention has a relatively remarkable proliferation inhibition effect on HER-2 positive breast cancer cells SK-Br-3, the effect is obviously superior to that of HER-2 negative breast cancer cells MCF-7, the compound can be used for preparing antitumor drugs, and a new way is opened up for deep research and development of tumor drugs in the future. The preparation method provided by the invention is simple and feasible, relatively high in yield and easy for large-scale production.

Synthesis and antiviral activity of novel 1,3,4-thiadiazole inhibitors of DDX3x

The human ATPase/RNA helicase X-linked DEAD-box polypeptide 3 (DDX3X) emerged as a novel therapeutic target in the fight against both infectious diseases and cancer. Herein, a new family of DDX3X inhibitors was designed, synthesized, and tested for its inhibitory action on the ATPase activity of the enzyme. The potential use of the most promising derivatives it has been investigated by evaluating their anti-HIV-1 effects, revealing inhibitory activities in the low micromolar range. A preliminary ADME analysis demonstrated high metabolic stability and good aqueous solubility. The promising biological profile, together with the suitable in vitro pharmacokinetic properties, make these novel compounds a very good starting point for further development.

PhI-Catalyzed Intramolecular Oxidative Coupling Toward Synthesis of 2-Amino-1,3,4-Thiadizoles

A highly efficient method for the synthesis of thiadiazole derivatives via intramolecular oxidative coupling of thiosemicarbazide, using the in situ generated hypervalent iodine(III) reagents is developed. The protocol can be carried out smoothly and provides a variety of thiadiazole derivatives in moderate to excellent yields. Graphical Abstract: A highly efficient method for the synthesis of thiadiazole derivatives via PhI-catalyzed intramolecular oxidative coupling of thiosemicarbazide has been developed.